Here's Why Jim Cramer Is Positive About Valeant Pharmaceuticals
Jim Cramer was encouraged by the slew of drug approvals Valeant Pharmaceuticals received from the FDA.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer was encouraged by the slew of drug approvals Valeant Pharmaceuticals (VRX) received from the FDA, according an article from TheStreet's Real Money team. 'I've been negative on Valeant because of its balance sheet,' Cramer said, referring to the company's high levels of debt.
